Anand Vaidya1, Gary C Curhan1, Julie M Paik1, Henry Kronenberg1, Eric N Taylor1. 1. Division of Endocrinology, Diabetes, and Hypertension (A.V.), Division of Renal Medicine (G.C.C., J.M.P.), Channing Division of Network Medicine (G.C.C., J.M.P., E.N.T.), Brigham and Women's Hospital (A.V., G.C.C., J.M.P., E.N.T.), and Endocrine Unit (H.K.), Massachusetts General Hospital, Harvard Medical School (A.V., G.C.C., J.M.P., H.K.), Boston, Massachusetts 02115; and Division of Nephrology and Transplantation (E.N.T.), Maine Medical Center, Portland, Maine 04102.
Abstract
CONTEXT: Hypertension is associated with higher PTH levels, and specific antihypertensive medications may modulate PTH. Whether hypertension or the use of specific antihypertensive medications influences the risk of developing incident primary hyperparathyroidism (P-HPTH) is not known. OBJECTIVE: The purpose of this study was to investigate whether a history of hypertension and the use of specific antihypertensive medications determine the risk for developing P-HPTH in a large prospective study. DESIGN/PARTICIPANTS: A longitudinal prospective cohort of female nurses in the Nurses' Health Study I (n = 75 600), who did not have P-HPTH at baseline and completed a questionnaire assessment of lifetime history of P-HPTH were followed from 1986 to 2008. Most participants were white and postmenopausal. SETTING: The study was a nationwide cohort study. MAIN OUTCOME MEASURE: Incident P-HPTH was assessed initially via questionnaire and then was confirmed by medical record review. Cox proportional hazards models were used to adjust for potential confounders. RESULTS: We documented 347 incident cases of P-HPTH during 1 719 416 person-years of follow-up. The age-adjusted relative risk (RR) for incident P-HPTH associated with hypertension was 1.80 (95% confidence interval [CI], 1.43-2.26), and the multivariate-adjusted RR was 1.45 (95% CI, 1.10-1.91). Among participants with a history of hypertension, the use of furosemide, when compared with the use of other antihypertensive medications, was associated with increased risk for developing P-HPTH; age-adjusted RR for incident P-HPTH was 1.79 (95% CI, 1.15-2.79) and multivariate-adjusted RR was 1.71 (95% CI, 1.08-2.71). CONCLUSIONS: In a large longitudinal prospective cohort study of mostly older white women, a history of hypertension and use of furosemide were associated with a significantly higher risk of developing P-HPTH.
CONTEXT: Hypertension is associated with higher PTH levels, and specific antihypertensive medications may modulate PTH. Whether hypertension or the use of specific antihypertensive medications influences the risk of developing incident primary hyperparathyroidism (P-HPTH) is not known. OBJECTIVE: The purpose of this study was to investigate whether a history of hypertension and the use of specific antihypertensive medications determine the risk for developing P-HPTH in a large prospective study. DESIGN/PARTICIPANTS: A longitudinal prospective cohort of female nurses in the Nurses' Health Study I (n = 75 600), who did not have P-HPTH at baseline and completed a questionnaire assessment of lifetime history of P-HPTH were followed from 1986 to 2008. Most participants were white and postmenopausal. SETTING: The study was a nationwide cohort study. MAIN OUTCOME MEASURE: Incident P-HPTH was assessed initially via questionnaire and then was confirmed by medical record review. Cox proportional hazards models were used to adjust for potential confounders. RESULTS: We documented 347 incident cases of P-HPTH during 1 719 416 person-years of follow-up. The age-adjusted relative risk (RR) for incident P-HPTH associated with hypertension was 1.80 (95% confidence interval [CI], 1.43-2.26), and the multivariate-adjusted RR was 1.45 (95% CI, 1.10-1.91). Among participants with a history of hypertension, the use of furosemide, when compared with the use of other antihypertensive medications, was associated with increased risk for developing P-HPTH; age-adjusted RR for incident P-HPTH was 1.79 (95% CI, 1.15-2.79) and multivariate-adjusted RR was 1.71 (95% CI, 1.08-2.71). CONCLUSIONS: In a large longitudinal prospective cohort study of mostly older white women, a history of hypertension and use of furosemide were associated with a significantly higher risk of developing P-HPTH.
Authors: Stefan Pilz; Andreas Tomaschitz; Christiane Drechsler; Eberhard Ritz; Bernhard O Boehm; Tanja B Grammer; Winfried März Journal: Eur Heart J Date: 2010-05-02 Impact factor: 29.983
Authors: Lars Rejnmark; Peter Vestergaard; Lene Heickendorff; Frederik Andreasen; Leif Mosekilde Journal: J Bone Miner Res Date: 2005-10-10 Impact factor: 6.741
Authors: Andreas Tomaschitz; Eberhard Ritz; Burkert Pieske; Jutta Rus-Machan; Katharina Kienreich; Nicolas Verheyen; Martin Gaksch; Martin Grübler; Astrid Fahrleitner-Pammer; Peter Mrak; Hermann Toplak; Elisabeth Kraigher-Krainer; Winfried März; Stefan Pilz Journal: Metabolism Date: 2013-10-02 Impact factor: 8.694
Authors: A J van Ballegooijen; M Visser; M F Cotch; A E Arai; M Garcia; T B Harris; L J Launer; G Eiríksdóttir; V Gudnason; I A Brouwer Journal: J Clin Endocrinol Metab Date: 2013-04-12 Impact factor: 5.958
Authors: Jenifer M Brown; Jonathan S Williams; James M Luther; Rajesh Garg; Amanda E Garza; Luminita H Pojoga; Daniel T Ruan; Gordon H Williams; Gail K Adler; Anand Vaidya Journal: Hypertension Date: 2013-11-04 Impact factor: 10.190
Authors: Marc Blondon; Michael Sachs; Andrew N Hoofnagle; Joachim H Ix; Erin D Michos; Claudia Korcarz; Adam D Gepner; David S Siscovick; Joel D Kaufman; James H Stein; Bryan Kestenbaum; Ian H de Boer Journal: Arterioscler Thromb Vasc Biol Date: 2013-06-27 Impact factor: 8.311
Authors: Sarah Zaheer; Ian de Boer; Matthew Allison; Jenifer M Brown; Bruce M Psaty; Cassianne Robinson-Cohen; Joachim H Ix; Bryan Kestenbaum; David Siscovick; Anand Vaidya Journal: J Bone Miner Res Date: 2016-02-15 Impact factor: 6.741